Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office For A Return To Big Science

Biogen Idec appoints a veteran biotech scientist/businessman to lead its newly restructured R&D efforts, which will focus on therapeutics for neurology and immunology. This appointment comes on the heels of a series of recent licensing agreements between Biogen and Neurimmune (, Amorfix ( and Knopp ( for the development of promising ALS therapeutics.

Click here to read more.

Share this: